Selected Publications

Press Release - Barcelona, June 7, 2015 Mobile Chamber Experts GmbH (MCX) Partners with Ora, Inc. to Bring Mobile Allergy Research Platform to the World

Mobile Chamber Experts GmbH (MCX), a provider of mobile allergen platforms for safe clinical modeling of allergic disease, has partnered with Ora, Inc., a US-based global clinical research and product development firm, to provide an international allergen chamber clinical research platform. The companies announced their collaboration at the annual congress of EAACI (European Academy of Allergy and Clinical Immunology) in Barcelona today.

Lanier, Abelson, Berger, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexodenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.

Clin Ther 1002;24(7):1161-74.

Spangler, Abelson, Ober, Gomes. Randomized, doublemasked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofendine hydrochloride tablets using the conjunctival and nasal allergen challenge models.

Clin Ther 2003;25(8):22245-67.

Berger, Abelson, Gomes, et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.

Ann Allergy Asthma Immunol 2005;95(4):361-71.

P. Gomes, M.B. Abelson, K. Lane, E. Angjeli. Development of a Standardized Clinician-Graded Scale for Assessment of Nasal Turbinate Inflammation Induced by Exposure to the Allergen BioCube

Journal of Allergy and Clinical Immunology, Volume 127, Issue 2, Supplement, February 2011, Page AB53.

M.B. Abelson, P. Gomes, K. Lane, N. Arenas. Signs and Symptoms of Allergic Rhinitis Produced by the Allergen BioCube Compared to the Environment: A Validation Study

Journal of Allergy and Clinical Immunology, Volume 127, Issue 2, Supplement, February 2011, Page AB253

Total Clinical Services
Download PDF »

Ora provides turnkey Allergy Drug Development and Commercialization services from product inception to post marketing approval. Our Allergy team is at the ready to execute with our disease categorized and pre qualified site network (OraNet), actively maintained patient databases and on-site “feet-on-the-ground” approach to conducting clinical research studies